Results 11 to 20 of about 3,125,328 (279)

CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1 [PDF]

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers.
Yijing Zhang, Han Gao, Aiwen Tang, Haiwen Lyu, Zongmin Fan, Jiahui Guo, Yuzhi Wang, Hairong Yi, Qihao Pan, Haidan Luo, Baifu Qin, Boyu Zhang, Xiangqi Meng, Qingxin Liu, Mong‐Hong Lee   +14 more
doaj   +3 more sources

Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

FASEB BioAdvances
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related mortality, characterized by intrinsic resistance to conventional therapies and limited effective treatment options. In this study, we investigated the role of the CXCR2
Caitlin Molczyk, Reegan Sturgeon, Sugandha Saxena, Esther Johnson, Rakesh Bhatia, Namita Bhyravbhatla, Sushil Kumar, Surinder K. Batra, Rakesh K. Singh   +8 more
doaj   +3 more sources

EGR1/LINC00839/SOX5 axis modulates migration, invasion and Gemcitabine resistance of bladder cancer cells [PDF]

Cancer Biology & Therapy, 2023
Background Bladder cancer is one of the most common malignant tumors of the urinary system, and its incidence is increasing worldwide. However, the underlying mechanisms that trigger migration, invasion and chemotherapy resistance are unclear.
Zunxian Wang, Bo Wei, Shuxia Ma
semanticscholar   +2 more sources

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer [PDF]

Biomolecules
Oral microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) and may contribute to chemotherapy resistance. While previous studies attributed bacteria-induced resistance to indirect host modulation, recent findings suggest a direct ...
Geng Xu, Yaling Jiang, Chen Sun, Bernd W. Brandt, Kamran Nazmi, Luca Morelli, Giulia Lencioni, Elisa Giovannetti, Dongmei Deng   +8 more
doaj   +2 more sources

Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer. [PDF]

Mol Cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer morbidity and mortality worldwide. The prognosis of patients has been significantly improved by chemotherapy, but acquired drug resistance remains a major obstacle to NSCLC treatment ...
Du X, Luo W, Li H, Gu Q, Huang P, Wang C, Li N, Liu F, Xia C.   +8 more
europepmc   +2 more sources

Integrated transcriptomic analysis identifies lactylation-linked gemcitabine resistance and therapeutic targets in intrahepatic cholangiocarcinoma [PDF]

Frontiers in Cell and Developmental Biology
BackgroundIntrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy of the bile ducts, and resistance to gemcitabine, a first-line chemotherapy, significantly complicates treatment.
Wenwei Xie, Wenwei Xie, Jialiang Hu, Jialiang Hu, Hanmei Xu, Hanmei Xu   +5 more
doaj   +2 more sources

TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism. [PDF]

Adv Sci (Weinh)
Pancreatic cancer (PC) progresses rapidly, and gemcitabine‐based chemotherapy has brought only limited efficacy. Identifying key drivers and therapeutic targets holds significant clinical value.
Fan X, Dai Y, Mo C, Li H, Luan X, Wang B, Yang J, Jiao G, Lu X, Chen Z, Liao Y, Qu L, Yang H, Lou C, Liu C, Li Z.   +15 more
europepmc   +2 more sources

The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability [PDF]

Cell Death and Disease
Gemcitabine resistance is a major clinical challenge in pancreatic cancer (PC); therefore, strategies to combat gemcitabine resistance are urgently required. Reprogramming pyrimidine metabolism by oncogenic signaling contributes to cancer progression and
Wenming Zhang, Rui Liu, Junwen Hu, Shuangyan Wan, Yeqin Zou, Tong Che, Jin Zhang, Leifeng Chen, Xiaogang Peng   +8 more
doaj   +2 more sources

Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation

Cell Death and Disease, 2021
Cancer-associated fibroblasts (CAFs) contribute to malignant progression and chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, little is known about the underlying mechanism.
Lusheng Wei, Qing Lin, Yanan Lu, Guolin Li, Leyi Huang, Zhiqiang Fu, Rufu Chen, Quanbo Zhou   +7 more
doaj   +2 more sources

BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. [PDF]

Cancers (Basel)
Simple Summary Further investigation into the molecular mechanisms of chemotherapy resistance in pancreatic cancer is crucial for improving the prognosis of pancreatic cancer patients.
Wang W, Zhou X, Kong L, Pan Z, Chen G.
europepmc   +2 more sources